Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05951777 · ClinicalTrials.gov registry record · Phase 2
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
A Phase 2 study of Traumatic Brain Injury, sponsored by Hope Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT05951777: Recruiting Phase 2 study of Traumatic Brain Injury, sponsored by Hope Biosciences.
NCT05951777 is a Phase 2 study of Traumatic Brain Injury that is actively recruiting participants, run by Hope Biosciences. The registered enrollment target is 51 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05951777, a Phase 2 study of Traumatic Brain Injury, is actively recruiting participants, sponsored by Hope Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury.
Primary Outcome
clinical lab evaluation of level of glucose in the blood (mg/dL)
Conditions Studied
Interventions
- DRUG Normal Saline
- BIOLOGICAL Autologous HB-adMSCs
Study Locations (2)
Texas
- Memorial Hermann Hospital / UTHealth McGovern Medical School at Houston - Houston
- The University of Texas Health Science at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2024-04-16 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT05951777 shows while recruiting
NCT05951777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT05951777 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05951777 about?
NCT05951777 is a clinical study titled "Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury". The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic...
What is the current status of trial NCT05951777?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2024-04-16. Estimated completion is 2026-12.
What conditions does trial NCT05951777 study?
This clinical trial studies the following conditions: Traumatic Brain Injury.
What interventions are being tested in trial NCT05951777?
The interventions under investigation include: Normal Saline (DRUG), Autologous HB-adMSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT05951777?
This trial is sponsored by Hope Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05951777 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05951777's enrollment target sits among peer trials
51 115th of 171 higher than 57 of 171 other Traumatic Brain Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)
RECRUITING · Phase 2
-
Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)
RECRUITING · Phase 2
-
Hyperbaric Oxygen Brain Injury Treatment Trial
RECRUITING · Phase 2
-
High Intensity Step Training After Traumatic Brain Injury
RECRUITING · Phase 2
-
Sildenafil for Microvasculopathy in Chronic TBI
RECRUITING · Phase 2
-
Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI